 |
Research
& Development:
A Passion for Science in the Service of Health
 A
Message from Elliott Sigal, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President,
Research and Development
The Bristol-Myers
Squibb Research and Development (R&D) organization is one of
the world's most innovative, productive, and respected scientific
research
organizations.
Our purpose is: to discover and develop innovative, cost-effective
medicines that address significant unmet medical needs and enhance
and extend human life. Moreover, R&D is an extraordinary
area in which to work—thanks to 7,000 employees’ remarkable talent,
dedication, and passion for using science to improve human health.
In
less than four years, R&D has delivered eight new drugs. By
industry standards, this places Bristol-Myers Squibb among the
most productive pharmaceutical companies in the world today.
New products
include treatments for several major disease areas, including cancer,
psychiatric disorders, HIV/AIDS, hepatitis B, and rheumatoid
arthritis.
In
addition, our research and development activities—centered
in four major U.S. facilities and numerous other facilities
in the
U.S. and worldwide—are creating and sustaining an outstanding pipeline.
Compounds with exciting potential are progressing through discovery,
exploratory development, and full development expeditiously. With
an intense focus on areas of significant
unmet medical need, we are working
to discover and develop treatments specifically for:
- cancer
- atherosclerosis/thrombosis
- diabetes
- obesity
- psychiatric disorders
- Alzheimer’s disease
- hepatitis
- HIV/AIDS
- rheumatoid arthritis
- and solid organ transplant rejection.
To
achieve our ambitious goals in these areas, we are aggressively
leveraging a broad
range of strategies and tools. For example, our scientists are
pioneering the use of genomics and pharmacogenomics to discover
and characterize
new compounds. In addition, we have created alliances with other
research organizations in order to respond swiftly to new opportunities
and thereby increase our success rate. Moreover, we recognize
that
gaining approval from the FDA or other health agencies around the
globe does not mark the end of our development work. We are committed
to unlocking the full value of the products we discover and develop;
thus, through life cycle management, we devote extensive resources
to identifying and fulfilling all the ways in which our products
can extend and enhance human life.
I
invite you to explore this site to learn more about the R&D focus,
our outstanding pipeline,
state-of-the-art facilities
around the world, our extraordinarily talented and committed people,
and alliance partnerships. I am
confident that you will learn much here about R&D and the great
company of which it is a vital part.
Last
updated, May 2007
|
